Search
Search Results
##search.searchResults.foundPlural##
-
MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA
2723PDF: 814HTML: 6493Untitled: 204Untitled: 167Untitled: 163Untitled: 188 -
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4511PDF: 2711HTML: 2223 -
MANAGEMENT OF ACUTE PROMYELOCYTIC LEUKEMIA IN THE ELDERLY
2690PDF: 1066HTML: 3252 -
TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS
2726PDF: 973HTML: 5494 -
TYROSINE KINASE INHIBITORS AND INTERFERON
2796PDF: 1388HTML: 3037Cover Letter: 180 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3226PDF: 1425HTML: 3970 -
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
3811PDF: 1429HTML: 9169Untitled: 255Untitled: 158Untitled: 148Untitled: 143Untitled: 162Untitled: 315 -
TOLL-LIKE RECEPTORS IN CHRONIC LYMPHOCYTIC LEUKEMIA
2508PDF: 834HTML: 17439Fig1 Caligaris: 142Fig.2 Caliga: 176 -
“IDENTIFYING HIGH-RISK CHRONIC LYMPHOCYTIC LEUKEMIA: A PATHOGENESIS-ORIENTED APPRAISAL OF PROGNOSTIC AND PREDICTIVE FACTORS IN PATIENTS TREATED WITH CHEMOTHERAPY WITH OR WITHOUT IMMUNOTHERAPY.”
3953PDF: 1007HTML: 3555Untitled: 162Cneo. Fig.1: 96Untitled: 88Untitled: 109Untitled: 110 -
INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER
3141PDF: 900HTML: 2923 -
INFECTIOUS COMPLICATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA
3199PDF: 1307HTML: 2604 -
NOVEL AGENTS AND EMERGING STRATEGIES FOR TARGETING THE B-CELL RECEPTOR PATHWAY IN CLL
2430PDF: 808HTML: 8786Efremov 1: 204Efremov 2: 161 -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
2161PDF: 1001HTML: 1971Characteristic of study group: 175 -
EPIDEMIOLOGY OF THERAPY-RELATED MYELOID NEOPLASMS IN THE NORDIC COUNTRIES
2129PDF: 768HTML: 1604Figure 1: 159Table 1: 184 -
IMMUNOGLOBULIN GENE REPERTOIRE IN CHRONIC LYMPHOCYTIC LEUKEMIA: INSIGHT INTO ANTIGEN SELECTION AND MICROENVIRONMENTAL INTERACTIONS
2969PDF: 830HTML: 7148Kost Fig1: 163Kost Fig 2: 154Kost Fig3: 149Kost Fig 4: 166Kost Fig5: 162Kost fig 6: 149 -
DIAGNOSIS AND SUBCLASSIFICATION OF ACUTE LYMPHOBLASTIC LEUKEMIA
8827PDF: 5934HTML: 87443Fig.1b: 159Fig.1c: 164Fig.2a: 155Fig.2b: 154Fig.4: 168Fig.2c: 154Fig.3: 161Tab.1: 209Tab.2: 187Tab.3: 175Tab.4: 195Fig1a: 155 -
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH AIDA BASED REGIMEN
3751PDF: 725HTML: 1822 -
CANDIDA ASSOCIATED BLOODSTREAM INFECTIONS IN PEDIATRIC HEMATOLOGY PATIENTS: SINGLE CENTER EXPERIENCE
4290PDF: 866HTML: 1297Table1: 164 -
THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA
2394PDF: 755HTML: 1720 -
ROLE OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA
2740PDF: 1182HTML: 2665Figure 1: 145 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2497PDF: 701HTML: 2281 -
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2200PDF: 1288HTML: 17051Bassan Fig.1: 133Bassan Fig.2: 129Bassan Fig.4: 125Fig.3: 162 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
4553PDF: 1280HTML: 1884Untitled: 163Untitled: 161 -
Massive pulmonary embolism at the onset of acute promyelocytic leukemia
3406PDF: 833HTML: 1620figure 1: 148Untitled: 170 -
A MULTICENTER EXPERIENCE FROM LEBANON IN CHILDHOOD AND ADOLESCENT ACUTE MYELOID LEUKEMIA:HIGH RATE OF EARLY DEATH IN CHILDHOOD ACUTE PROMYELOCYTIC LEUKEMIA.
2009PDF: 1083HTML: 7668cover letter paper final AML: 192 -
Tacrolimus Associated Posterior Reversible Encephalopathy Syndrome – A Case Series and Review
3458PDF: 1440HTML: 4274CoverLetter: 167Figure1: 174 -
Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated Acute Myeloid leukemia- A case report and review of literature
1809PDF: 868HTML: 1738Sorafenib induced Hand Foot Skin Rash in FLT3 ITD mutated AML- IMAGES: 142 -
Complex and Multifaceted Therapy-Related Myeloid Neoplasm Following Laryngeal Cancer Treated with Cisplatin and Radiotherapy
1130PDF: 706HTML: 1327Figure 1: 153Figure 2: 150 -







